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Abstract 
Objective: Both Tourette’s Disorder (TD) and Attention-Deficit/Hyperactivity Disorder 
(ADHD) have been related to abnormalities in glutamatergic neurochemistry in the fronto-
striatal circuitry. TD and ADHD often co-occur and the neural underpinnings of this co-
occurrence have been insufficiently investigated in prior studies.  
Method: We used proton magnetic resonance spectroscopy (1H-MRS) in children between 8-
12 years of age (TD n=15, ADHD n=39, TD+ADHD n=29, and healthy controls n=53) as an 
in vivo method of evaluating glutamate concentrations in the fronto-striatal circuit. Spectra 
were collected on a 3 Tesla Siemens scanner from two voxels in each participant: the anterior 
cingulate cortex (ACC) and the left dorsal striatum. LC-model was used to process spectra 
and generate glutamate concentrations in institutional units. A one-way analysis of variance 
was performed to determine significant effects of diagnostic group on glutamate 
concentrations. 
Results: We did not find any group differences in glutamate concentrations in either the ACC 
(F(3,132)=0.97, p=0.41) or striatum (F(3,121)=0.59, p=0.62). Furthermore, variation in glutamate 
concentration in these regions was unrelated to age, sex, medication use, IQ, tic, or ADHD 
severity. Obsessive-compulsive (OC) symptoms were positively correlated with ACC 
glutamate concentration within the participants with TD (rho=0.35, puncorrected=0.02). 
Conclusion: We found no evidence for glutamatergic neuropathology in TD or ADHD within 
the fronto-striatal circuits. However, the correlation of OC-symptoms with ACC glutamate 
concentrations suggests that altered glutamatergic transmission is involved in OC-symptoms 
within TD, but this needs further investigation. 
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1. Introduction 
Tourette’s Disorder (TD) and Attention-Deficit/Hyperactivity Disorder (ADHD) are early 
onset neurodevelopmental disorders affecting approximately 1%
1
 and 5%
2
 of children and 
adolescents, respectively. While TD is characterized by the presence of motor and vocal tics
3
 
there are also psychiatric comorbidities present in up to 86% of those with TD during their 
lifetime.
4
 ADHD is the most common, occurring in approximately 40% of cases
5
 and even 
more TD patients have ADHD symptoms that do not meet the threshold for diagnosis.
6
 
Conversely, the presence of tics within patients with ADHD has been estimated at 20%.
7
 
ADHD itself is characterized by age inappropriate inattention and/or hyperactivity/impulsivity 
leading to impaired functioning.
3
  
Both disorders have been associated with abnormalities in fronto-striatal circuits,
8,9
 
although the overlap in conditions has confounded research to date. Structural and functional 
neuroimaging studies have reported alterations in the caudate nuclei, putamen, and anterior 
cingulate cortex (ACC) in TD
10,11
 and ADHD
12–14
 relative to controls, although not always 
consistently. It has been proposed that excitatory abnormalities in the striatum cause 
erroneous inhibition of neurons in the globus pallidus (GP) internus, which in turn leads to 
disinhibition of prefrontal neurons which results in tic phenomena.
15
 These striatal 
abnormalities may also underlie the high rate of comorbidity with other disorders, like ADHD 
and obsessive compulsive disorder (OCD)
4
 due to the aberrant integrative interplay of 
different fronto-striatal circuits including connections with the ACC.
15,16
Dopamine 
dysfunction within the fronto-striatal circuit has long been considered the primary cause of 
tics
17
 and has been related to difficulties with attention and impulsivity.
18
 However, as 
glutamatergic, GABAergic, serotonergic, cholinergic, and opioid as well as dopaminergic 
systems all operate within the fronto-striatal circuits it is plausible that multiple 
neurotransmitter systems may be involved in TD and ADHD.
19
 Glutamate is the primary 
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excitatory neurotransmitter found in the brain,
20,21
 essential in fronto-striatal transmission and 
often co-transmitted with dopamine.
22
 Post-mortem analysis of a small number of brains from 
people who had TD corroborate the view that glutamate is involved in TD as reduced levels 
of glutamate were seen in the GP and substantia nigra of the TD brains compared to control 
brains.
23
 
Additional insights into the underlying neurobiology of TD and ADHD can be found 
by investigating brain neurochemistry. This can be achieved by using proton magnetic 
resonance spectroscopy (1H-MRS) which allows for non-invasive in vivo quantification of 
specific neurometabolites. There have been just four MRS studies of TD to date, three of 
which focused on GABA concentrations either in the primary and secondary motor areas
24
 or 
the sensory motor cortex.
25,26
 DeVito and colleagues
27
 on the other hand investigated multiple 
neurochemicals including Glx, the combined signal from glutamatergic compounds 
(glutamate+glutamine), within multiple regions; premotor cortex, caudate nucleus, putamen 
and thalamus with a 3 Tesla scanner in a sample of 25 (male only) children and adolescents 
with TD in comparison to controls. No group differences were seen in Glx in any of the 
regions. Within the putamen lower creatine (Cre) levels bilaterally and lower N-acetyl 
aspartate and choline in the left putamen were found. Reduced Cre bilaterally in the caudate 
nucleus was also seen but this did not reach significance. 
Many more MRS studies of disorders related to TD, such as ADHD and OCD, have 
been conducted. For a review of these studies in ADHD, OCD and autism spectrum disorder 
(ASD) see Naaijen and colleagues.
28
 However, findings were inconsistent, plagued by 
heterogeneous methodologies, sample selection (i.e., child or adult, inclusion or exclusion of 
comorbidities), voxel placement, and often inadequate field strengths to distinguish glutamate 
from glutamine.
28
 Despite these issues the review tentatively summarized increased striatal 
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Glx levels are associated with both ADHD and OCD and increased ACC Glx levels with 
pediatric ADHD. 
 In the current study we assessed a large number of children between the ages of 8-12 
years which allowed us to focus on a group where tics are most frequently observed and not 
limit ourselves to the subset of patients whose tics persist into adulthood.
29
 Furthermore we 
directly addressed the confounds of comorbidity rampant in previous studies by including a 
TD+ADHD group in addition to ADHD, TD, and healthy control (HC) groups. Based on 
previous findings in childhood ADHD,
28
 we expected increased glutamate concentrations in 
both regions of interest. This is the first study to investigate fronto-striatal glutamate in 
children with TD. Given the theory that excitatory abnormalities in the striatum result in tics, 
we expected to observe raised glutamate in the striatum of TD patients.     
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2. Method 
2.1 Participants 
Participants with TD and/or ADHD: TD with/without ADHD n=60, ADHD without TD n=60 
were recruited via child and adolescent psychiatry departments and patient associations 
throughout the Netherlands, while healthy controls (HC; n=60) were found mainly through 
schools. The final numbers included for analysis (i.e. with usable data) can be found in 
section 3.1 and Table 1 (n=136 for the ACC and n=125 for the striatum). Written informed 
consent was provided by the parents/guardians of all participants and written assent was also 
given by participants who were 12 years of age. This study was approved by the regional 
ethics board (CMO Regio Arnhem-Nijmegen, numbers: NL42004.091.12 & 
NL48377.091.14). 
Inclusion criteria for all participants included being aged 8-12 years, IQ>70, 
Caucasian decent, no previous head injuries or neurological disorders, no contra indications 
for MRI assessment, and no major physical illness. Inclusion criteria for ADHD and TD were 
meeting DSM-5 criteria for these disorders. Those with sub-threshold ADHD (Kiddie 
Schedule for Affective Disorders and Schizophrenia (K-SADS
30
) score of 4 or 5 on either 
subscale) were also included. Persistent Motor or Vocal Tic Disorder (Motor type) was also 
allowed for the TD group. Common psychiatric comorbidities like oppositional defiant 
disorder were not excluded. Within the TD group, ADHD, and OCD were not excluded, while 
in the ADHD group those with tics and/or OCD were excluded. Within the HC group no 
psychiatric disorders were allowed, as determined by screening questionnaires (Child 
behavior checklist [CBCL] and Teacher Report Form [TRF]
31
). Subjects were divided into 
four groups; HC, TD, ADHD, and TD+ADHD, see Table 1 for demographics. Participants 
were required to refrain from consuming caffeine on the day of testing. Medications for tics 
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were continued as normal while stimulant medication was withheld for 48 hours before 
testing. 
 
2.2 Phenotypic information 
TD diagnosis was confirmed, and tic severity rated, by diagnostic interview with parent(s) and 
child present using the Yale Global Tic Severity Scale (YGTSS
32
). To determine the presence 
of ADHD and/or other psychiatric disorders the K-SADS
30
 interview was administered to the 
parent(s). All interviews were conducted by experienced researchers who were trained and 
overseen by a child- and adolescent psychiatrist (JKB). The screening module was used, 
followed if needed by disorder-specific modules. If participants screened positive for possible 
OCD the Children’s Yale-Brown Obsessive Compulsive Scale (CY-BOCS33) was 
administered with both parent(s) and child present. The CY-BOCS interview was conducted 
with each participant of the TD group due to the relatedness of symptoms and common co-
occurance of OCD and TD.  
 Full-scale IQ was estimated by four subtests of the Wechsler Intelligence Scale for 
Children-III (WISC-III
34
): Vocabulary, Similarities, Block design, and Picture completion. 
Questionnaires were further used to assess phenotypic traits. The Conners’ Parent Rating 
Scale – Revised Long version (CPRS-RL35) was used to rate ADHD severity. Additional 
questionnaires were used to assess the presence of autistic symptoms and compulsive 
behaviors; the Children’s Social Behavioral Questionnaire (CSBQ36) and Repetitive Behavior 
Scale (RBS-R
37
). Information about medication history was gathered from parental report 
which has previously been shown to correlate well with pharmacy records.
38
 Interviews on 
psychiatric symptoms were conducted about an unmedicated period.  
 
2.3  T1-weighted MRI acquisition 
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All MRI datasets were acquired on the same 3T Siemens Prisma (Siemens, Erlangen, 
Germany) scanner located in the Donders Institute for Brain, Cognition and Behaviour, 
Nijmegen, the Netherlands. T1-weighted anatomical images were acquired with a transversal, 
3D magnetization prepared rapid gradient echo (MPRAGE) parallel imaging sequence with 
the following parameters: TR = 2300 ms, TE = 2.98 ms, TI = 900 ms, FoV = 256 mm, slice 
thickness = 1.20 mm, Flip angle 9 degrees, in plane resolution = 1.0×1.0 mm, acceleration 
factor = 2, acquisition time = 5:30 min. Each participant also had their head stabilized with 
cushions during scanning and had a piece of tape across their foreheads to help awareness of 
possible movement while scanning. All participants were first familiarized with the MRI 
procedure in a mock scanner where the importance of lying still was explained.  
 
2.4 MRS acquisition 
Proton spectra were acquired using a point resolved spectroscopy (PRESS) sequence in two 
regions of interest, with chemically selective suppression (CHESS) water suppression.
39
 A 
single 8 cm
3
 voxel was centered on the midline covering the pregenual ACC anterior and 
slightly superior to the genu of the corpus callosum (TR = 3000 ms, TE = 30 ms, number of 
averages = 96, bandwidth = 5 kHz, number of points = 4096). A second, similar voxel was 
located in the left dorsal striatum covering the caudate nucleus and putamen. Unsuppressed 
water reference spectra (16 averages) were also acquired as part of the standard acquisition. 
See Figure 1 for location of the voxels and an example spectrum. Both voxels were placed to 
include a maximum amount of grey matter and a minimum amount of cerebrospinal fluid 
(CSF). T1-weighted images were used for voxel placement and later for tissue segmentation 
during processing. Acquisition time was six minutes per voxel.  
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Figure 1. Location of the two voxels are shown on a T1-weighted anatomical image for the 
pregenual ACC including an example spectrum (top) and the left dorsal striatum including an 
example spectrum (bottom). Peaks corresponding to individual metabolites are highlighted. 
The thin black line represents the frequency-domain data, the red line is the LCModel fit. In 
the top panel the residuals are plotted (the data minus the fit).  Cho, Choline; Cre, creatine; 
Gln, glutamine; Glu, glutamate; Glx, Glu+Gln; mI, myo-inositol; NAA, N-Acetylaspartate.  
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2.5 Processing 
LCModel, version V6.03-0I,
40,41
 was used to conduct spectral analysis. LCModel uses a linear 
combination of simulated or in vitro metabolite solution spectra as a reference to identify and 
quantify the major resonance of in vivo spectra.  
 Water referenced metabolite concentrations were automatically calculated in 
institutional units (i.u.). Institutional units are presented since we did not correct for the T1 
and T2 relaxation times of the metabolites or the T1 relaxation time of water. The T2 of tissue 
water was corrected for assuming the signal had decayed by 30% at the echo time.
42
 No 
correction was made for the T2 decay of metabolites. In addition, there are other scanner-
dependent factors that can affect the absolute scaling (e.g., details of coil combination), such 
that metabolite concentrations measured in i.u. are preferred over attempting to scale to 
absolute concentrations in millimolar (mM). The unified segmentation procedure within the 
VBM8 toolbox of SPM8 (Statistical Parametric Mapping release 8, London, UK) was used to 
process the T1 images and produce grey matter (GM), white matter (WM), and CSF 
probability maps. Spectroscopy voxels were mapped onto these maps to provide the partial 
volume of GM, WM, and CSF within each spectroscopy voxel (fGM, fWM, and fCSF), and to 
allow for group comparisons of the placement of the spectroscopy voxels. Additionally, to 
correct for differing amounts of water in each tissue and for partial volume effects we 
corrected individual metabolite concentrations for water concentrations with the following 
formula
43
: 
 
Metabolitecorrected 
 = MetaboliteRaw * ((43300 * fGM + 35880 * fWM + 55556 * fCSF)/35880) * (1/(1 - fCSF)) 
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where 43300, 35880, and 55556 are the water concentrations in mM for GM, WM, and 
CSF,
44
 respectively, as described by the LCModel manual.
45
 These concentrations correspond 
to 77.9, 64.4 and 100%, respectively, assuming that CSF is pure water.
44
 This includes a 
correction for the fraction of the MRS voxel occupied by CSF, along with corrections for the 
water concentration in each of the tissue types. The factor 35880 in the denominator is 
included since the initial LCModel analysis was carried out assuming the voxel was pure WM. 
 
2.6 Quality control 
Statistical analyses were restricted to spectra with linewidth (full-width at half-maximum; 
FWHM) ≤0.1 ppm, Cramér-Rao lower bounds (CRLB) ≤20%, signal to noise ratio ≥5 or 
corrected glutamate concentrations less than two standard deviations from the mean. 
Furthermore, anatomical scan quality was visually checked as these were used for voxel 
placement and tissue segmentation. Fifteen participants were excluded from both analyses due 
to poor structural scan quality. A further seven spectra from the ACC (n=136) and 20 spectra 
from the striatal analyses (n=125) were excluded based on spectral quality. In addition to the 
exclusion of those with ≥20% CRLB values, we investigated group differences in CRLBs to 
verify that possible differences in glutamate levels were not due to differences in CRLBs.
46
 
 
2.7 Statistics 
Statistical analyses were conducted with the R statistical program.
47
 Differences between the 
four groups in categorical measures were tested with Pearson’s chi-squared tests. Group 
differences in continuous measures were assessed with a one way analysis of variance 
(ANOVA) or Welch Two Sample t-test if assumptions of homogeneity of variance and 
normality of distributions were met (p>0.05 in Bartlett test of homogeneity of variance and 
Shapiro-Wilk normality test). If these assumptions were violated a non-parametric Kruskal-
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Wallis rank sum test was used. ADHD severity was only tested between the ADHD and 
TD+ADHD group. Similarly measures related to tics and OC-symptoms were only tested 
between the TD and TD+ADHD groups. 
 Group differences in voxel tissue composition and spectral quality were assessed with 
a ANOVA. Group differences in glutamate were analyzed first with age and sex included as 
covariates. These covariates were removed from analysis as they did not significantly 
contribute to the model. This resulted in the use of an ANOVA followed if appropriate by 
Bonferroni corrected post-hoc pairwise t-tests. The influence of IQ, ADHD severity, ASD 
symptoms, repetitive and compulsive behaviors, and medication status were also examined by 
inclusion in an ANCOVA. Correlations between glutamate levels and phenotypic measures of 
those with TD (tic severity, age of onset and duration since tic onset, and OC-symptoms) were 
assessed with Pearson’s correlation tests if normally distributed or Spearman’s rank 
correlation rho test if not. Tests were then Bonferroni corrected for multiple comparisons. In 
the supplementary material we added the same analysis for Glx. 
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3. Results 
3.1 Demographics 
MR spectra were acquired for a total of 162 of the original 180 participants. Three 
participants from the ADHD group were found not to have ADHD (K-SADS <4 in both 
subscales) and one presented with tics but did not meet criteria for TD or Chronic Motor Tic 
disorder (CMT). These four participants were thereafter excluded from analysis. Due to 
spectral or segmentation quality concerns 22 spectra were excluded from the ACC analysis 
(n=136) and 35 from the striatal analysis (n=125). The TD group was subdivided into those 
that also had ADHD (TD+ADHD; n=29, 27 for the ACC and striatal analyses, respectively) 
and those that did not (TD; n=15, 17 for the ACC and striatal analyses, respectively). 
Participants with sub-threshold ADHD were included in either the ADHD group or the 
TD+ADHD group if comorbid with TD. Details of the groups used for analysis of the ACC 
are reported in Table 1 (n=136).  
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Table 1. Demographic description of participants included in the ACC analysis 
 
Control TD ADHD TD+ADHD 
Test 
statistic 
p-value 
N 53 15 39 29   
Age years, 
mean(SD) 
10.0(1.0) 10.4(1.2) 10.7(1.2) 10.7(1.6) 
K-W 
χ2=2.98 
0.40 
Sex, m/f 38/15 13/2 21/18 25/4 χ2=10.70 0.01* 
a
IQ, mean(SD) 
Range 
109(11), 86 – 
133 
105(12), 81 – 
126 
103(13), 71 – 
137 
106(11), 85 – 
124 
F=2.47 0.06 
Handed, r/l 48/5 14/1 36/3 25/4 χ2=0.90 0.82 
b
ADHD severity, 
mean(SD) 
T=45.5(4.9)  
I=45.5(6.0)  
H=46.1(3.7) 
T=51.7(7.0)  
I=50.9(8.2) 
H=52.2(8.5)  
T=71.9(9.7)  
I=69.3(10.0)  
H=71.2(11.1) 
T=68.7(9.1) 
I=65.2(9.8) 
H=70.0(10.4) 
t=1.37 
t=1.69 
t=-0.44 
0.18† 
0.10† 
0.66† 
CSBQ core 
autism score, 
mean(SD) 
1.42(1.89) 9.53(10.58) 12.46(7.78) 17.66(9.40)   
RBS 
compulsivity 
score, mean(SD) 
0.09(0.35) 1.67(1.59)  0.69(1.24) 2.55(3.00)   
c
Tic dx, n 
- 
TD=14 
CMT=1 
- TD=29   
c
Tic severity, 
mean(SD) 
- 
T=20.4(7.9) 
M=13.6(4.3) 
V=6.8(4.7) 
- 
T=20.8(9.2) 
M=13.1(5.5) 
V=7.7(5.7) 
t=-0.13 
t=0.33 
K-W 
χ2=0.22 
0.89 
0.75 
0.64 
c
Age tic onset 
years, mean(SD) 
- 5.3(1.7) - 5.7(1.7) t=-0.75 0.46 
c
Duration since 
tic onset years, 
mean(SD)
 
- 5.0(1.8) - 5.0(2.0) t=0.06 0.95 
d
OCD dx, n - 3 - 6   
d
OC-symptoms, 
mean(SD) 
- 8.47(8.6) - 6.75(8.4) 
K-W χ2 
=0.78 
0.38 
e
Medication  
Stimulant 
Strattera 
Antipsychotic 
Clonidine
 
- 
 
0 
0 
2 
0 
 
24 
1 
1 
0 
 
9 
0 
7 
2 
  
a
IQ estimated from a subtest of the Wechsler Intelligence Scale for Children-III (WISC-III
34
) 
rating. 
b
ADHD severity ratings reflect T-scores from the Conners’ Parent Rating Scale – 
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Revised Long version.
35
 
c
Tic diagnosis and severity were determined and rated with the Yale 
Global Tic Severity Scale.
32
 Tic severity is reported excluding impairment score. 
d
OCD 
diagnosis was determined as a total-score of ≥16 on the Children’s Yale-Brown Obsessive 
Compulsive Scale.
33
 
e
Current medication status, determined from parental report of current 
and previous medication use. †Statistics refer to an ADHD versus TD+ADHD contrast. 
*p<0.05, **p<0.01. ADHD, Attention-Deficit/Hyperactivity Disorder; CSBQ, Children’s 
Social Behavioral Questionnaire; CMT, Chronic Motor Tic; dx, diagnosis; H, hyperactive; I, 
inattentive; C, combined; K-W, Kruskal-Wallis; M, motor; m/f, male/female; OCD, 
Obsessive Compulsive Disorder; r/l, right/left; RBS, Repetitive Behavior Scale; SD, standard 
deviation; t, Welch Two sample t-test; T, total; TD, Tourette’s Disorder; V, vocal.  
 
Analysis of the striatum included fewer participants (n=125) due to exclusion based on 
spectral quality (n=22). This did not significantly alter the demographic distributions between 
groups (n=48, 17, 33, and 27 for the HC, TD, ADHD, and TD+ADHD groups, respectively) 
regarding age (K-W χ2=1.64, p=0.65), sex (χ2=8.09, p=0.04), IQ (F(3,117)=2.25, p=0.09) and 
handedness (χ2=0.82, p=0.84). ADHD severity between the ADHD and TD+ADHD groups 
differed slightly but not significantly with respect to total and inattentive scores (t=1.90, 
p=0.06; t=1.84, p=0.07; t=0.99, p=0.33 for total, inattentive, and hyperactive CPRS scores, 
respectively) while tic severity (t=0.31, p=0.76; t=-0.54, p=0.59; K-W χ2=~0, p=0.99 for total, 
motor, and vocal YGTSS scores respectively) and OC-symptoms (K-W χ2=1.52, p=0.22) 
remained similar between the TD and TD+ADHD groups. 
 Age of tic onset (t=-0.51, p=0.62) and duration since tic onset (t=-0.06, p=0.95) did not 
differ significantly between the TD and the TD+ADHD group. For both analyses sex was not 
balanced between groups, mainly due to a low number of girls with TD having been included. 
This reflects the proportionately fewer girls affected by TD compared to boys.
48
 Sex was 
included in the model to account for this imbalance, however, it was found not to affect the 
model significantly and was therefore subsequently removed. 
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3.2 Spectral quality 
Groups did not differ significantly in mean voxel percentage GM, WM or CSF in either ACC 
(F(3,132)=0.30, p=0.83, F(3,132)=0.61, p=0.61 and F(3,132)=0.26, p=0.85, respectively) or striatum 
(F(3,121)=1.77, p=0.16, F(3,121)=1.77, p=0.16 and F(3,121)=1.73, p=0.16, respectively). In the 
ACC voxel across all groups the tissue percentages were: GM 70 (7)%, WM 11 (2)% and 
CSF 18 (7)%. For the striatal voxel these were GM 58 (7)%, WM 42 (7)% and CSF 1 (1)%.   
To verify that the spectral quality did not differ between the groups, we compared the 
CRLB estimated standard deviations in both of the voxels, using a one-way ANOVA across 
the four groups. CRLB’s did not differ between groups in the ACC (F(3,132)=1.35, p=0.26) or 
the striatum (F(3,121)=0.37, p=0.77). Furthermore all CRLB’s were in the range 3-7% SD, all 
SNR were > 20 and all FWHM were in the range of 0.02-0.09 reflecting overall good quality 
of the ACC spectrum in all four groups. For the striatum, CRLB’s were in the range 5-17%, 
SNR were > 11 and FWHM were in the range of 0.04-0.09.  
 
3.3 ACC 
Age and sex had no significant influence on the ANCOVA model and were subsequently 
excluded. There was no group difference in corrected glutamate levels ANOVA (F(3, 132)=0.97, 
p=0.41, Figure 2). There was no influence of IQ (p=0.61), total CPRS ADHD severity T-
score (p=0.56), inattentive CPRS T-score (p=0.70), hyperactive CPRS T-score (p=0.48), 
CSBQ core autism symptom-score (p=0.64) or RBS compulsivity score (p=0.92). Current 
medication use showed no significant effect on glutamate levels when any current medication 
(p=0.65), current stimulant medication (p=0.28) or current antipsychotic medication (p=0.56) 
were investigated.  
There were no correlations in those with tics between corrected glutamate concentrations and 
tic severity (total p=0.77, motor p=0.40, vocal p=0.53), duration since (p=0.38) or age of 
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onset (p=0.16). A significant positive correlation (rho=0.35) between ACC glutamate and 
CY-BOCS total score (p=0.02) was found. This correlation was also present for the 
obsessions (rho=0.30, p=0.045) and compulsions (rho=0.31, p=0.04) severity scales 
separately. However, the two subscales were highly correlated (rho=0.55, p<0.001). However, 
none of the correlations with glutamate concentration survived correction for multiple 
comparisons (12 correlation analyses). The analysis was limited to the participants that were 
administered the CY-BOCS (n=44, all with TD). 
 
3.4 Striatum 
Similarly for the striatal analysis there were no significant effects of age or sex on glutamate 
levels. Group analysis revealed no difference in striatal corrected glutamate levels (F(3, 
121)=0.59, p=0.62, Figure 2). Again there was no influence of IQ (p=0.63), total CPRS ADHD 
severity T-score (p=0.78), inattentive CPRS T-score (p=0.80), hyperactive CPRS T-score 
(p=0.75), CSBQ core autism symptom score (p=0.37), RBS compulsivity score (p=0.25) or 
current medication use (any p=0.73, stimulant p=0.80 or antipsychotic p=0.06). There were 
no correlations between corrected glutamate concentrations and tic severity (total p=0.34, 
motor p=0.46 vocal p=0.22), duration since (p=0.19) or age of onset (p=0.08). There was no 
association between glutamate and CY-BOCS total score (rho=-0.25, p=0.11). 
 
3.5 Glx 
There were also no group differences in Glx concentration in either the ACC or striatum (see 
supplementary information for details).  
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Figure 2. Boxplots of glutamate concentrations per group in the ACC and striatum. No group 
differences in glutamate levels were seen. ADHD, attention-deficit/hyperactivity disorder; 
HC, healthy controls; i.u., Institutional Units; TD, Tourette’s disorder; TD+ADHD, Tourette’s 
disorder and comorbid attention-deficit/hyperactivity disorder. 
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Figure 3. Correlation of ACC glutamate concentration with obsessive-compulsive symptoms 
(CY-BOCS total score) in participants with TD. ACC, anterior cingulate cortex; CY-BOCS, 
Children’s Yale-Brown Obsessive Compulsive Scale; i.u., Institutional Units; TD, Tourette’s 
disorder. The solid line and its shaded area denote the linear regression fit line and its 95% 
confidence interval. 
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4. Discussion 
This is the first study to investigate glutamate concentrations in both TD and ADHD together. 
We found no group differences in ACC or left striatal glutamate concentrations. The findings 
were not confounded by any demographic differences between the groups, spectral quality, 
medication use or OC-symptoms. Glutamate levels in the ACC correlated with OC-symptoms 
within the participants with TD (n=44) but did not relate to either tic or ADHD measures of 
severity.  
Only one previous study examined glutamate concentrations in TD by investigating 
the combined Glx signal in children and adolescents and they were unable to find Glx 
differences in the brain regions investigated. In corroboration with results presented here 
(both Glx and glutamate analyses) they found no difference in the putamen but unfortunately 
did not also examine the ACC.
27
 Previous studies did, however, suggest glutamate 
involvement in TD although the nature of this is yet unclear with both hyper- and hypo-
glutamatergic states being hypothesized.
19
 For instance, a post-mortem analysis by Anderson 
and colleagues
23
 showed reduced glutamate levels in the GP and substantia nigra of those 
with TD, while a study investigating serum glutamate concentrations showed increased levels 
in adult TD patients compared to controls.
49
 Our current findings do not support the 
hypothesis of glutamatergic involvement in the fronto-striatal network in TD. 
The current study found no difference in those with ADHD compared to healthy 
controls or any association between glutamate levels and ADHD severity scores in either the 
ACC or striatum. Previous studies have been confounded by methodological issues but do 
appear to show increased Glx levels in both these regions in pediatric ADHD compared to 
controls,
28
 an observation not replicated here, and reduced striatal Glx in adults with ADHD.
50
 
Associations with symptom severity have been reported previously in adults with ADHD in 
which negative correlations between inattentive symptoms and glutamate-to-creatine ratios in 
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the ACC
51
 or Glx levels in the basal ganglia
50
 were  reported. However, these studies were 
performed in adults, who differ in both ADHD symptoms
2
 and glutamate levels
52
 compared to 
children.  
Possibly the most interesting finding of the current study, however, is the potential 
positive correlation between ACC glutamate levels and OC-symptoms within participants 
with TD. The correlation was present also for both the obsessions and compulsions subscales 
separately. This suggests the association with ACC glutamate concentration relates to the 
severity of OC-symptoms irrespective of these dimensions. Elevated ACC glutamate may be 
associated with cognitive control deficits related to obsessions and compulsions.
53
 However, 
these findings failed to survive correction for multiple comparisons so should be interpreted 
with caution. Previous literature investigating associations with symptom severity in OCD 
samples have also shown positive correlations with glutamatergic compounds. For instance, 
correlations between Glx levels in dorsal and rostral ACC
54
 and caudate nucleus
55
 and total 
symptom severity as measured with the Y-BOCS were reported before, although only in adult 
samples. Our findings should, however, only be interpreted in relation to OC-symptoms 
within TD. No studies so far have examined glutamatergic compounds in childhood TD and 
OCD together. Further studies are required to see if the current trend-findings extend to OC-
symptoms within pediatric OCD and across other disorders that exhibit similar behaviors, 
such as ASD. Furthermore, this is a child sample of participants and how these findings 
relates to OC-symptoms in adult TD will remain unclear until further research is conducted.  
The current study ranks among the first to use MRS to investigate brain neurochemical 
concentrations in TD and is the very first to investigate glutamate concentrations in both TD 
and ADHD together. However, the study was limited by the small number of TD participants 
who presented without ADHD/sub-threshold ADHD, these figures are in line with what is 
expected given the high comorbidity rates of ADHD in TD.
4
 It is unlikely that this 
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significantly hindered the study as our null findings regarding tics and ADHD are supported 
by the lack of correlations between symptom severity and glutamate levels. These results 
should not be extrapolated to adults as glutamate concentrations change with age
52
 and adult 
ADHD and TD may well constitute specific presentations of TD and ADHD that persist from 
childhood. Many participants were medicated, which may alter glutamate levels. However, as 
the effect of current medication use did not influence glutamate concentrations in either the 
ACC or striatum medication use was unlikely to have confounded our results. There are 
several additional factors that may influence glutamatergic signalling such as time of day, 
sleep, food intake etc. for which we unfortunately could not control.
56,57
 Future work is 
needed to confirm the influence of these factors. Most questionnaires were answered about an 
un-medicated period, however, a small number of parents opted to answer about a medicated 
period as they were more familiar with this behavior, this may have led to inconsistent 
measures of symptom severity in a few cases. Finally, due to low spatial resolution in MRS 
studies (i.e. large ROIs) it is difficult to determine regionally specific glutamatergic 
alterations. This is particularly relevant for the striatum ROI, which may contain functionally 
independent areas with regard to caudate nucleus and putamen. Further investigation should 
be undertaken to confirm the relation of OC-symptoms and glutamate concentrations in other 
disorders (OCD, ASD) and also in adult cohorts to determine if the association within TD is 
limited to children with TD or also present in adult TD.    
 In conclusion, we found no support for alterations in glutamatergic transmission in the 
fronto-striatal circuit of children with either ADHD, TD or a combined diagnosis. However, 
the current study suggests glutamatergic alterations in the ACC in relation to OC-symptoms 
within children with TD.  
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Highlights 
 
- Large pediatric sample of ADHD and TD participants  
- 3 Tesla proton MRS utilized to investigate fronto-striatal glutamate concentrations 
- No differences in glutamate concentrations in the disorder groups compared with controls 
- ACC glutamate concentrations associated with obsessive-compulsive symptoms in TD 
